193 related articles for article (PubMed ID: 22524153)
1. No correlation between the expression of FXR and genes involved in multidrug resistance phenotype of primary liver tumors.
Martinez-Becerra P; Vaquero J; Romero MR; Lozano E; Anadon C; Macias RI; Serrano MA; Grañé-Boladeras N; Muñoz-Bellvis L; Alvarez L; Sangro B; Pastor-Anglada M; Marin JJ
Mol Pharm; 2012 Jun; 9(6):1693-704. PubMed ID: 22524153
[TBL] [Abstract][Full Text] [Related]
2. Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib.
Herraez E; Lozano E; Macias RI; Vaquero J; Bujanda L; Banales JM; Marin JJ; Briz O
Hepatology; 2013 Sep; 58(3):1065-73. PubMed ID: 23532667
[TBL] [Abstract][Full Text] [Related]
3. Activation of the nuclear receptor FXR enhances hepatocyte chemoprotection and liver tumor chemoresistance against genotoxic compounds.
Vaquero J; Briz O; Herraez E; Muntané J; Marin JJ
Biochim Biophys Acta; 2013 Oct; 1833(10):2212-9. PubMed ID: 23680185
[TBL] [Abstract][Full Text] [Related]
4. Knockdown of ATP8B1 expression leads to specific downregulation of the bile acid sensor FXR in HepG2 cells: effect of the FXR agonist GW4064.
Martínez-Fernández P; Hierro L; Jara P; Alvarez L
Am J Physiol Gastrointest Liver Physiol; 2009 May; 296(5):G1119-29. PubMed ID: 19228886
[TBL] [Abstract][Full Text] [Related]
5. Up-regulation of FXR isoforms is not required for stimulation of the expression of genes involved in the lack of response of colon cancer to chemotherapy.
Martinez-Becerra P; Monte I; Romero MR; Serrano MA; Vaquero J; Macias RI; Del Rio A; Grañé-Boladeras N; Jimenez F; San-Martin FG; Pastor-Anglada M; Marin JJ
Pharmacol Res; 2012 Nov; 66(5):419-27. PubMed ID: 22898327
[TBL] [Abstract][Full Text] [Related]
6. Bcl-2 gene silencing in pediatric epithelial liver tumors.
Warmann SW; Frank H; Heitmann H; Ruck P; Herberts T; Seitz G; Fuchs J
J Surg Res; 2008 Jan; 144(1):43-8. PubMed ID: 17574594
[TBL] [Abstract][Full Text] [Related]
7. VCC-1 over-expression inhibits cisplatin-induced apoptosis in HepG2 cells.
Zhou Z; Lu X; Zhu P; Zhu W; Mu X; Qu R; Li M
Biochem Biophys Res Commun; 2012 Apr; 420(2):336-42. PubMed ID: 22425983
[TBL] [Abstract][Full Text] [Related]
8. Upregulated miR-182 increases drug resistance in cisplatin-treated HCC cell by regulating TP53INP1.
Qin J; Luo M; Qian H; Chen W
Gene; 2014 Apr; 538(2):342-7. PubMed ID: 24447717
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of human farnesoid X receptor by miR-421 promotes proliferation and migration of hepatocellular carcinoma cells.
Zhang Y; Gong W; Dai S; Huang G; Shen X; Gao M; Xu Z; Zeng Y; He F
Mol Cancer Res; 2012 Apr; 10(4):516-22. PubMed ID: 22446874
[TBL] [Abstract][Full Text] [Related]
10. The expression of genes involved in hepatocellular carcinoma chemoresistance is affected by mitochondrial genome depletion.
Gonzalez-Sanchez E; Marin JJ; Perez MJ
Mol Pharm; 2014 Jun; 11(6):1856-68. PubMed ID: 24824514
[TBL] [Abstract][Full Text] [Related]
11. FXR-dependent and -independent interaction of glucocorticoids with the regulatory pathways involved in the control of bile acid handling by the liver.
Rosales R; Romero MR; Vaquero J; Monte MJ; Requena P; Martinez-Augustin O; Sanchez de Medina F; Marin JJ
Biochem Pharmacol; 2013 Mar; 85(6):829-38. PubMed ID: 23313557
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin-induced downregulation of miR-199a-5p increases drug resistance by activating autophagy in HCC cell.
Xu N; Zhang J; Shen C; Luo Y; Xia L; Xue F; Xia Q
Biochem Biophys Res Commun; 2012 Jul; 423(4):826-31. PubMed ID: 22713463
[TBL] [Abstract][Full Text] [Related]
13. Wilms' tumor 1 gene expression in hepatocellular carcinoma promotes cell dedifferentiation and resistance to chemotherapy.
Perugorria MJ; Castillo J; Latasa MU; Goñi S; Segura V; Sangro B; Prieto J; Avila MA; Berasain C
Cancer Res; 2009 Feb; 69(4):1358-67. PubMed ID: 19190340
[TBL] [Abstract][Full Text] [Related]
14. Critical role of farnesoid X receptor for hepatocellular carcinoma cell proliferation.
Fujino T; Takeuchi A; Maruko-Ohtake A; Ohtake Y; Satoh J; Kobayashi T; Tanaka T; Ito H; Sakamaki R; Kashimura R; Ando K; Nishimaki-Mogami T; Ohkubo Y; Kitamura N; Sato R; Kikugawa K; Hayakawa M
J Biochem; 2012 Dec; 152(6):577-86. PubMed ID: 22969091
[TBL] [Abstract][Full Text] [Related]
15. Farnesoid X receptor associates with β-catenin and inhibits its activity in hepatocellular carcinoma.
Liu X; Zhang X; Ji L; Gu J; Zhou M; Chen S
Oncotarget; 2015 Feb; 6(6):4226-38. PubMed ID: 25650661
[TBL] [Abstract][Full Text] [Related]
16. Mybl2 expression is under genetic control and contributes to determine a hepatocellular carcinoma susceptible phenotype.
Frau M; Ladu S; Calvisi DF; Simile MM; Bonelli P; Daino L; Tomasi ML; Seddaiu MA; Feo F; Pascale RM
J Hepatol; 2011 Jul; 55(1):111-9. PubMed ID: 21419759
[TBL] [Abstract][Full Text] [Related]
17. Hepatocellular carcinoma and chemotherapy: the role of p53.
Brito AF; Abrantes AM; Pinto-Costa C; Gomes AR; Mamede AC; Casalta-Lopes J; Gonçalves AC; Sarmento-Ribeiro AB; Tralhão JG; Botelho MF
Chemotherapy; 2012; 58(5):381-6. PubMed ID: 23257706
[TBL] [Abstract][Full Text] [Related]
18. Bile salt export pump is dysregulated with altered farnesoid X receptor isoform expression in patients with hepatocellular carcinoma.
Chen Y; Song X; Valanejad L; Vasilenko A; More V; Qiu X; Chen W; Lai Y; Slitt A; Stoner M; Yan B; Deng R
Hepatology; 2013 Apr; 57(4):1530-41. PubMed ID: 23213087
[TBL] [Abstract][Full Text] [Related]
19. Opsin3 sensitizes hepatocellular carcinoma cells to 5-fluorouracil treatment by regulating the apoptotic pathway.
Jiao J; Hong S; Zhang J; Ma L; Sun Y; Zhang D; Shen B; Zhu C
Cancer Lett; 2012 Jul; 320(1):96-103. PubMed ID: 22313545
[TBL] [Abstract][Full Text] [Related]
20. [Antitumor effects of soluble TRAIL in human hepatocellular carcinoma].
He SQ; Chen Y; Chen XP; Zhang WG; Wang HP; Zhao YZ; Wang SF
Zhonghua Zhong Liu Za Zhi; 2003 Mar; 25(2):116-9. PubMed ID: 12795833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
